The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Abstract
The HSG described the important benefit of tetrabenazine (TBZ) in patients with Huntington disease.1 We would like to stress the mechanism of action of this valuable agent. The only action ascribed to TBZ in achieving the clinical benefit was inhibiting presynaptic vesicular monoamine transporters to block amine reuptake and secondarily decrease dopamine levels. Although this mechanism is clearly established, TBZ is also functionally effective as a dopamine receptor antagonist based on a large body of rigorous literature. This additional mechanism could well contribute to the clinical benefit observed and possibly explain some unexpected results. In support of an independent action as a dopaminergic antagonist, TBZ blocks dopamine-2 and apomorphine-mediated3 inhibition of pituitary prolactin release in vivo2,3 …
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale
Johns, M. W. (1991) · Sleep · doi:10.1093/sleep/14.6.540 · Cited by 17,364
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Unified Huntington's disease rating scale: Reliability and consistency
(1996) · Movement Disorders · doi:10.1002/mds.870110204 · Cited by 2,079
Unified Huntington's disease rating scale: reliability and consistency
Kremer, H. P. H. (1996) · Radboud Repository (Radboud University) · Cited by 1,059
Erickson, J. D., Schafer, M. K., Bonner, T. I., Eiden, L. E., & Weihe, E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.5166 · Cited by 479
Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Huntington Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000198586.85250.13 · Cited by 471
Long-term effects of tetrabenazine in hyperkinetic movement disorders
Jankovic, J., & Beach, J. (1997) · Neurology · doi:10.1212/wnl.48.2.358 · Cited by 352
Farrer, L. A., Opitz, J. M., & Reynolds, J. F. (1986) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320240211 · Cited by 243
Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias
Jankovic, J., & Orman, J. (1988) · Neurology · doi:10.1212/wnl.38.3.391 · Cited by 231
Treatment of hyperkinetic movement disorders with tetrabenazine: A double‐blind crossover study
Jankovic, J. (1982) · Annals of Neurology · doi:10.1002/ana.410110108 · Cited by 162
Cited by
Walker, F. O. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60111-1 · Cited by 2,603
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743
Huntington's disease: a clinical review
Roos, R. A. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-40 · Cited by 1,037
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Calcium signaling and neurodegenerative diseases
Bezprozvanny, I. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.001 · Cited by 469
Metadata
- Authors
- Savani, A. A., & Login, I. S.
- Venue
- Neurology
- Published
- 2007-03-06
- Volume
- 68
- Issue
- 10
- Pages
- 797-797
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1992305831
- Cited by
- 299
- References
- 34
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. https://app.cochat.ai/papers/10.1212/01.wnl.0000259143.52138.5c
- The paper
- Savani, A. A., & Login, I. S. (2007). Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology. https://doi.org/10.1212/01.wnl.0000259143.52138.5c
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.